Key result
Guidewire-based measurement of FFR and IMR using intravenous adenosine was safe in STEMI and NSTEMI patients, with 0 serious adverse events and a 0.3% overall rate of coronary dissection.
Why the study?
Is guidewire-based measurement of FFR and IMR using intravenous adenosine safe in patients with acute or recent myocardial infarction?
Cohort (n=648)
Yes
Is guidewire-based measurement of FFR and IMR using intravenous adenosine safe in patients with acute or recent myocardial infarction?
Guidewire-based measurement of FFR and IMR using intravenous adenosine is safe in patients with acute or recent myocardial infarction, with a very low risk of coronary dissection.
Supports safety consideration in acute MI; leaves open need for randomized confirmation before routine use.
AIMS: Coronary guidewire-based diagnostic assessments with hyperemia may cause iatrogenic complications. We assessed the safety of guidewire-based measurement of coronary physiology, using intravenous adenosine, in patients with an acute coronary syndrome. METHODS: We prospectively enrolled invasively managed STEMI and NSTEMI patients in two simultaneously conducted studies in 6 centers (NCT01764334; NCT02072850). All of the participants underwent a diagnostic coronary guidewire study using intravenous adenosine (140 μg/kg/min) infusion for 1-2 min. The patients were prospectively assessed for the occurrence of serious adverse events (SAEs) and symptoms and invasively measured hemodynamics were also recorded. RESULTS: 648 patients (n=298 STEMI patients in 1 hospital; mean time to reperfusion 253 min; n=350 NSTEMI in 6 hospitals; median time to angiography from index chest pain episode 3 (2, 5) days) were included between March 2011 and May 2013. Two NSTEMI patients (0.3% overall) experienced a coronary dissection related to the guidewire. No guidewire dissections occurred in the STEMI patients. Chest symptoms were reported in the majority (86%) of patient's symptoms during the adenosine infusion. No serious adverse events occurred during infusion of adenosine and all of the symptoms resolved after the infusion ceased. CONCLUSIONS: In this multicenter analysis, guidewire-based measurement of FFR and IMR using intravenous adenosine was safe in patients following STEMI or NSTEMI. Self-limiting symptoms were common but not associated with serious adverse events. Finally, coronary dissection in STEMI and NSTEMI patients was noted to be a rare phenomenon.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2015) conducted a cohort in Acute coronary syndrome (STEMI and NSTEMI) (n=648). Guidewire-based measurement of FFR and IMR using intravenous adenosine was evaluated on Occurrence of serious adverse events (SAEs) and symptoms. Guidewire-based measurement of FFR and IMR using intravenous adenosine was safe in STEMI and NSTEMI patients, with 0 serious adverse events and a 0.3% overall rate of coronary dissection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: